SRC and neoplasm: Our results also confirmed that when src inhibition and gemcitabine were combined, anti-tumor effects (proliferation, migration, apoptosis and stemness) were maximized compared with either agent alone in gemcitabine-resistant triple-negative breast cancer cells.